Xencor

Biotechnology ResearchCalifornia, United States201-500 Employees

Xencor is a Pasadena-based biotechnology company focused on designing protein and antibody therapeutics for autoimmune diseases, asthma, and cancer. By applying proprietary protein engineering, it aims to enhance immune functions while retaining the favorable attributes of natural antibodies, potentially delivering more potent and longer-lasting medicines. The company reports a pipeline including eight antibody product candidates in human trials, developed in collaboration with pharmaceutical partners. It also pursues biosuperiors, seeking to improve existing antibody drugs to enhance performance and ease of use. Operating in the biotechnology research sector, Xencor serves pharmaceutical developers and, ultimately, patients who benefit from advanced biologics. In 2026, the company reported Phase 1 results for XmAb942 and preclinical data for XmAb412, and announced data presentations at Digestive Disease Week.

Sign up for free to view info

Email Format Employee directory